Literature DB >> 24973605

Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis.

Jost B Jonas1, Rupert R A Bourne2, Richard A White3, Seth R Flaxman4, Jill Keeffe5, Janet Leasher6, Kovin Naidoo7, Konrad Pesudovs8, Holly Price2, Tien Y Wong9, Serge Resnikoff10, Hugh R Taylor11.   

Abstract

PURPOSE: To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy.
DESIGN: Meta-analysis.
METHODS: Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded.
RESULTS: In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macular diseases. In 2010, macular diseases caused 6.6% (95% UI: 6.0, 7.9) of all blindness and 3.1% (95% UI: 2.7, 4.0) of all vision impairment, worldwide. These figures were lower in regions with young populations than in high-income regions. Between 1990 and 2010, the number of people who were blind or visually impaired due to macular diseases increased by 36%, or 0.6 million people (95% UI: 0.5, 0.8) and by 81%, or 2.7 million (95% UI: 2.6, 3.9) people, respectively, whereas the global population increased by 30%. Age-standardized global prevalence of macula-related blindness and vision impairment in adults 50 years of age and older decreased from 0.2% (95% UI: 0.2, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010 and remained unchanged from 0.4% (95% UI: 0.3, 0.5) to 0.4% (95% UI: 0.4, 0.6), respectively.
CONCLUSIONS: In 2010, 2.1 million people were blind and 6.0 million people were visually impaired due to macular diseases, except those caused by diabetic maculopathy. Of every 15 blind people, 1 was blind due to macular disease, and of every 32 visually impaired people, 1 was visually impaired due to macular disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24973605     DOI: 10.1016/j.ajo.2014.06.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  26 in total

Review 1.  Age-related macular degeneration.

Authors:  Monika Fleckenstein; Tiarnán D L Keenan; Robyn H Guymer; Usha Chakravarthy; Steffen Schmitz-Valckenberg; Caroline C Klaver; Wai T Wong; Emily Y Chew
Journal:  Nat Rev Dis Primers       Date:  2021-05-06       Impact factor: 52.329

2.  Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration.

Authors:  Xu Wang; Lian Zhao; Yikui Zhang; Wenxin Ma; Shaimar R Gonzalez; Jianguo Fan; Friedrich Kretschmer; Tudor C Badea; Hao-Hua Qian; Wai T Wong
Journal:  J Neurosci       Date:  2017-02-24       Impact factor: 6.167

3.  The Evolution of the Plateau, an Optical Coherence Tomography Signature Seen in Geographic Atrophy.

Authors:  Anna C S Tan; Polina Astroz; Kunal K Dansingani; Jason S Slakter; Lawrence A Yannuzzi; Christine A Curcio; K Bailey Freund
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-04-01       Impact factor: 4.799

4.  Microperimetry - A New Tool for Assessing Retinal Sensitivity in Macular Diseases.

Authors:  Memota Laishram; Krishnagopal Srikanth; A R Rajalakshmi; Swathi Nagarajan; G Ezhumalai
Journal:  J Clin Diagn Res       Date:  2017-07-01

5.  Plasma E-selectin levels can play a role in the development of diabetic retinopathy.

Authors:  Márta Kasza; J Meleg; J Vardai; B Nagy; E Szalai; J Damjanovich; A Csutak; B Ujhelyi; V Nagy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-04       Impact factor: 3.117

Review 6.  The role of lymphocytes and phagocytes in age-related macular degeneration (AMD).

Authors:  Verena Behnke; Anne Wolf; Thomas Langmann
Journal:  Cell Mol Life Sci       Date:  2020-01-02       Impact factor: 9.261

7.  Myeloid-resident neuropilin-1 promotes choroidal neovascularization while mitigating inflammation.

Authors:  Elisabeth M M A Andriessen; François Binet; Frédérik Fournier; Masayuki Hata; Agnieszka Dejda; Gaëlle Mawambo; Sergio Crespo-Garcia; Frédérique Pilon; Manuel Buscarlet; Karine Beauchemin; Véronique Bougie; Garth Cumberlidge; Ariel M Wilson; Steve Bourgault; Flavio A Rezende; Normand Beaulieu; Jean-Sébastien Delisle; Przemyslaw Sapieha
Journal:  EMBO Mol Med       Date:  2021-04-19       Impact factor: 12.137

Review 8.  Blue-light filtering intraocular lenses (IOLs) for protecting macular health.

Authors:  Laura E Downie; Ljoudmila Busija; Peter R Keller
Journal:  Cochrane Database Syst Rev       Date:  2018-05-22

Review 9.  Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness.

Authors:  Igor Khalin; Renad Alyautdin; Ganna Kocherga; Muhamad Abu Bakar
Journal:  Int J Nanomedicine       Date:  2015-04-30

10.  Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction.

Authors:  Dordi Austeng; Tora Sund Morken; Stine Bolme; Turid Follestad; Vidar Halsteinli
Journal:  BMC Ophthalmol       Date:  2016-10-01       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.